References

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.14412/1995-4484-2018-356-362

rsp-2572

Research Article

ПРОГРАММА НЕПРЕРЫВНОГО ПОСЛЕДИПЛОМНОГО ОБРАЗОВАНИЯ ВРАЧЕЙ

POSTGRADUATE PROGRAM OF CONTINUING MEDICAL EDUCATION

Внесуставные проявления ревматоидного артрита

EXTRA-ARTICULAR MANIFESTATIONS OF RHEUMATOID ARTHRITIS

Муравьев

Ю. В.

Muravyev

Yu. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

murawyu@mail.ru

ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

2018

15072018

563356362

2018

Муравьев Ю.В.

Muravyev Y.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/2572

Ревматоидный артрит (РА) – иммуновоспалительное (аутоиммунное) ревматическое заболевание неизвестной этиологии, характеризующееся хроническим эрозивным артритом и системным поражением внутренних органов, приводящее к ранней инвалидности и сокращению жизни больных. Для постановки диагноза в настоящее время рекомендуется применение классификационных критериев РА (ACR/EULAR, 2010), согласно которым при клиническом исследовании необходимо выявить хотя бы один припухший сустав, т. е. наличие артрита; очевидно, поэтому проблема внесуставных проявлений РА остается в тени.

Rheumatoid arthritis (RA) is an immune inflammatory (autoimmune) rheumatic disease of unknown etiology, which is characterized by chronic erosive arthritis and systemic damage to the viscera, and leads to early disability and reduced survival in patients. For its diagnosis, it is currently recommended to use the 2010 ACR/EULAR classification criteria for RA, which should be applied in clinical trials to identify at least one swollen joint, i.e. the presence of arthritis; therefore, the problem of extra-articular manifestations of RA is apparent to stay in the background.

внесуставные проявленияревматоидный артритревматоидный факторантитела к циклическому цитруллинированному пептиду

extra-articular manifestationsrheumatoid arthritisrheumatoid factoranti-cyclic citrullinated peptide antibodies

References1

Тареев ЕМ. К учению о так называемом неспецифическом инфекционном артрите. Советская медицина. 1953;(6):15-21 [Tareev EM. To the doctrine of the so-called nonspecific infectious arthritis. Sovetskaya Meditsina. 1953;(6):15-21 (In Russ.)].

Тареев ЕМ. Висцеральные поражения при системных васкулитах и ревматоидном артрите. Советская медицина. 1956;(5):10-8 [Tareev EM. Visceral lesions in systemic vasculitis and rheumatoid arthritis. Sovetskaya Meditsina. 1956;(5):10-8 (In Russ.)].

Астапенко МГ, Пихлак ЭГ. Болезни суставов. Москва: Медицина; 1966. С. 99-116 [Astapenko MG, Pikhlak EG. Bolezni sustavov [Diseases of the joints]. Moscow: Meditsina; 1966. P. 99-116 (In Russ.)].

Насонов ЕЛ, редактор. Клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2005. 288 с. [Nasonov EL, editor. Klinicheskie rekomendatsii. Revmatologiya [Clinical recommendations. Rheumatology]. Moscow: GEOTARMedia; 2005. 288 p. (In Russ.)].

Каратеев ДЕ, Олюнин ЮА. О классификации ревматоидного артрита. Научно-практическая ревматология. 2008;46(1):5-16 [Karateev DE, Olunin YuA. About classification of rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2008;46(1):5-16 (In Russ.)]. doi: 10.14412/1995-4484-2008-848

Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiyskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)].

Turesson C, O’Fallon WM, Crowson CS, Matteson EL. Occurrence of extra-articular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol. 2002;29:62-7.

Turesson C, Jacobsson L, Bergström U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford). 1999;38(7):668-74. doi: 10.1093/rheumatology/38.7.668

Das S, Padhan P. An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management. J Pharmacol Pharmacother. 2017;8(3):81-6.

Prete M, Racanelli V, Digiglio L, et al. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev. 2011;11(2):123-31. doi: 10.1016/j.autrev.2011.09.001

Turesson C, McClelland RL, Christianson TJ, Matteson EL. No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: Results from a community-based study. Arthritis Rheum. 2004;50:3729-31. doi: 10.1002/art.20590

Bartels C, Bell C, Rosenthal A, et al. Decline in rheumatoid vasculitis prevalence among US veterans: A retrospective cross-sectional study. Arthritis Rheum. 2009;60:2553-7. doi: 10.1002/art.24775

Бестаев ДВ, Каратеев ДЕ, Насонов ЕЛ. Системные проявления ревматоидного артрита. Научно-практическая ревматология. 2013;51(1):76-80 [Bestaev DV, Karateev DE, Nasonov EL. Systemic manifestations of rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(1):76-80 (In Russ.)]. doi: 10.14412/1995- 4484-2013-1206

Cronstein BN. Interleukin-6 – A key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(Suppl 1):S11-5.

Voskuyl AE, Zwinderman AH, Westedt ML, et al. Factors associated with the development of vasculitis in rheumatoid arthritis: Results of a case-control study. Ann Rheum Dis. 1996;55:190-2. doi: 10.1136/ard.55.3.190

Struthers GR, Scott DL, Delamere JP, et al. Smoking and rheumatoid vasculitis. Rheumatol Int. 1981;1:145-6. doi: 10.1007/BF00541260

Turesson C, Jacobsson L, Sturfelt G, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis. 2006;66:59-64. doi: 10.1136/ard.2006.054445

Rojas-Villarraga A, Diaz FJ, Calvo-Paramo E, et al. Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. J Autoimmun. 2009;32:64-9. doi: 10.1016/j.jaut.2008.11.004

Bergström U, Book C, Lindroth Y, et al. Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978. Scand J Rheumatol. 1999;28:160-5. doi: 10.1080/03009749950154239

Watts RA, Scott DG .Vasculitis and inflammatory arthritis. Best Pract Res Clin Rheumatol. 2016;30(5):916-31. doi: 10.1016/j.berh.2016.10.008

Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Buchar) 2010;5:286-91.

Saraux A, Allain J, Guedes C, et al. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol. 1996;35:752-4. doi: 10.1093/rheumatology/35.8.752

Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study. Arthritis Rheum. 2010;62:1583-91. doi: 10.1002/art.27405

Prete M, Racanelli V, Digiglio L, et al. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev. 2011;11:123-31. doi: 10.1016/j.autrev.2011.09.001

Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritisinterstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183:372-8. doi: 10.1164/rccm.201004-0622OC

Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127:2019-27. doi: 10.1378/chest.127.6.2019

Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: Associations, prognostic factors and physiological and radiological characteristics – A large multicentre UK study. Rheumatology (Oxford). 2014;53:1676-82. doi: 10.1093/rheumatology/keu165

Mori S. Management of rheumatoid arthritis patients with interstitial lung disease: Safety of biological antirheumatic drugs and assessment of pulmonary fibrosis. Clin Med Insights Circ Respir Pulm Med. 2015;9:41-9. doi: 10.4137/CCRPM.S23288

Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143:814-24. doi: 10.1378/chest.12-0741

De Lauretis A, Veeraraghavan S, Renzoni E. Review series: Aspects of interstitial lung disease: Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8:53- 82. doi: 10.1177/1479972310393758

Liote H. Pulmonary manifestation of rheumatoid arthritis. Rev Mal Respir. 2008;25:973-88.

Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-7. doi: 10.1161/01.CIR.0000054612.26458.B2

Ortega-Hernandez OD, Pineda-Tamayo R, Pardo AL, et al. Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis. Clin Rheumatol. 2009;28:767-75. doi: 10.1007/s10067-009-1145-8

Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford). 2006;45(Suppl 4):iv4-7. doi: 10.1093/rheumatology/kel313

Kitas G, Banks MJ, Bacon PA. Cardiac involvement in rheumatoid disease. Clin Med (Lond). 2001;1:18-21. doi: 10.7861/clinmedicine.1-1-18

Das S, Mohanty M, Padhan P. Outcome of rheumatoid arthritis following adjunct statin therapy. Indian J Pharmacol. 2015;47:605- 9. doi: 10.4103/0253-7613.169585

Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: Results from a community based study. Ann Rheum Dis. 2004;63:952-5. doi: 10.1136/ard.2003.018101

Agarwal V, Singh R, Wiclaf F, et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol. 2008;27:841-4. doi: 10.1007/s10067-007- 0804-x

Muramatsu K, Tanaka H, Taguchi T. Peripheral neuropathies of the forearm and hand in rheumatoid arthritis: Diagnosis and options for treatment. Rheumatol Int. 2008;28:951-7. doi: 10.1007/s00296-008-0630-8

Ito H, Neo M, Sakamoto T, et al. Subaxial subluxation after atlantoaxial transarticular screw fixation in rheumatoid patients. Eur Spine J. 2009;18:869-76. doi: 10.1007/s00586- 009-0945-5

Schett G, Hayer S, Zwerina J, et al. Mechanisms of disease: The link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol. 2005;1:47-54. doi: 10.1038/ncprheum0036

Mielants H, van den Bosch F. Extra-articular manifestations. Clin Exp Rheumatol. 2009;27:S56-61.

Korpela M, Mustonen J, Teppo AM, et al. Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis. Br J Rheumatol. 1997;36:1189-95. doi: 10.1093/rheumatology/36.11.1189

Balint GP, Balint PV. Felty’s syndrome. Best Pract Res Clin Rheumatol. 2004;18:631-45. doi: 10.1016/j.berh.2004.05.002

Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701. doi: 10.1002/art.21675

Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol. 2002;31:251-9. doi: 10.1080/030097402760375124

Felty AR. Chronic arthritis in the adult associated with splenomegaly and leucopenia. Bull Johns Hopkins Hospital. 1924;35:16-20.

Hanrahan EM, Miller SR. Effect of splenectomy in Felty’s syndrome. JAMA. 1932;99:1247-9. doi: 10.1001/jama.1932.02740670035010

Goldberg J, Pinals RS. Felty syndrome. Semin Arthritis Rheum. 1980;10:52-65. doi: 10.1016/0049-0172(80)90014-1

Barnes CG, Turnbull AL, Vernon-Roberts B. Felty’s syndrome. A clinical and pathological survey of 21 patients and their response to treatment. Ann Rheum Dis. 1971;30:359-74. doi: 10.1136/ard.30.4.359

Sienknecht CW, Urowitz MB, Pruzanski W, Stein HB. Felty’s syndrome. Clinical and serological analysis of 34 cases. Ann Rheum Dis. 1977;36:500-7. doi: 10.1136/ard.36.6.500

Campion G, Maddison PJ, Goulding N, et al. The Felty syndrome: a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine. 1990;69:69-80. doi: 10.1097/00005792-199069020-00001

Denko CW, Zumpft CW. Chronic arthritis with splenomegaly and leukopenia. Arthritis Rheum. 1962;5:478-91. doi: 10.1002/art.1780050505

Ruderman M, Miller LM, Pinals RS. Clinical and serological observations on 27 patients with Felty’s syndrome. Arthritis Rheum. 1968;11:377-84. doi: 10.1002/art.1780110302

Rosenstein ED, Kramer N. Felty’s and pseudo-Felty’s syndromes. Semin Arthritis Rheum. 1991;21(3):129-42. doi: 10.1016/0049- 0172(91)90002-H

Breedveld FC, Fibbe WE, Cats A. Neutropenia and infections in Felty’s syndrome. Brit J Rheumatol. 1988;27:191-7. doi: 10.1093/rheumatology/27.3.191

Cornwell GG, Zacharski LR. Neutropenia, elevated rheumatoid factor, splenomegaly, and absence of rheumatoid arthritis. Ann Intern Med. 1974;80:555-6. doi: 10.7326/0003-4819-80-4-555

Bradley JD, Pinals RS. Felty’s syndrome presenting without arthritis. Clin Exp Rheumatol. 1983;1:257-9.

Armstrong RD. Fernandes L, Gibson T, et al. Felty’s syndrome presenting without arthritis. Br Med J. 1983;287:1620. doi: 10.1136/bmj.287.6405.1620

Moore RA, Brunner CM, Sandusky WR, Leavell BS. Felty's syndrome: long-term follow-up after splenectomy. Ann Intern Med. 1971;75(3):381-5. doi: 10.7326/0003-4819-75-3-381

Bucknall RC, Davis P, Bacon PA, Jones JV. Neutropenia in rheumatoid arthritis: studies on possible contributing factors. Ann Rheum Dis. 1982;41:242-7. doi: 10.1136/ard.41.3.242

Thorne C, Urowitz MB. Long-term outcome in Felty’s syndrome. Ann Rheum Dis. 1982;41:486-9. doi: 10.1136/ard.41.5.486

Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013;25(3):360-6. doi: 10.1097/BOR.0b013e32835f693f

Watts RA, Ntatsaki E. Refractory rheumatoid vasculitis – a therapeutic dilemma. Oxf Med Case Reports. 2016;2016(11):omw081. doi: 10.1093/omcr/omw081

Ntatsaki E, Mooney J, Scott DGI, Watts RA. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology (Oxford) 2014;53:145-52. doi: 10.1093/rheumatology/ket326

Theander L, Nyhä ll-Wahlin BM, Nilsson JA, et al. Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors. J Rheumatol. 2017;44(7):981-7. doi: 10.3899/jrheum.161103

Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum. 2006;36:88-98. doi: 10.1016/j.semarthrit.2006.04.006

Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. J Rheumatol. 2005;32:759-60.

Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V. Should antitumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? J Rheumatol. 2006;33:433-4.

Puechal X, Miceli-Richard C, Mejjad O, et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis. 2008;67:880-4. doi: 10.1136/ard.2007.081679

Hellmann M, Jung N, Owczarczyk K, et al. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47:929-30. doi: 10.1093/rheumatology/ken129

Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, et al. Treatment of Raynaud’s phenomenon. Autoimmun Rev. 2008;8:62- 8. doi: 10.1016/j.autrev.2008.07.002

Turesson C, Matteson EL. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol. 2004;16:206-11. doi: 10.1097/00002281-200405000-00007

Turiel M, Sitia S, Atzeni F, et al. The heart in rheumatoid arthritis. Autoimmun Rev. 2010;9:414-8. doi: 10.1016/j.autrev.2009.11.002

Mielants H, van den Bosch F. Extra-articular manifestations. Clin Exp Rheumatol. 2009;27:S56-61.

Mrabet D, Meddeb N, Ajlani H, et al. Cerebral vasculitis in a patient with rheumatoid arthritis. Joint Bone Spine. 2007;74:201-4. doi: 10.1016/j.jbspin.2006.08.004

Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol. 2006;12:291-3. doi: 10.1097/01.rhu.0000249766.24780.95

Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol. 2010;29:559-61. doi: 10.1007/s10067-009-1368-8

Iaccheri B, Androudi S, Bocci EB, et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm. 2010;18:223-5. doi: 10.3109/09273941003739928

Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty's syndrome. Br J Rheumatol. 1998;37:908-11. doi: 10.1093/rheumatology/37.8.908

Lekharaju V, Chattopadhyay C. Efficacy of rituximab in Felty's syndrome. Ann Rheum Dis. 2008;67:1352. doi: 10.1136/ard.2007.078915

Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009;68:1235-6. doi: 10.1136/ard.2008.099267

Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010;29:1195-7. doi: 10.1007/s10067-010-1422-6

The authors declare that there are no conflicts of interest present.